ArticleCureus2025
Prevalence of Urinary Tract Infection and Urosepsis Following Transrectal Ultrasound-Guided Prostate Biopsy: Spectrum of Pathogens and Patterns of Antibiotic Resistance.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Transrectal ultrasound-guided prostate biopsy (TRUS-Bx) remains the global standard for diagnosing prostate cancer. Despite being a relatively safe procedure, it carries a risk of post-biopsy complications, most notably urinary tract infections (UTIs) and urosepsis. Increasing rates of antibiotic resistance, especially to fluoroquinolones, have raised concerns about the safety of TRUS-Bx in many regions. Data from Pakistan remain limited, prompting this study to investigate infectious complications and resistance profiles in a local tertiary care setting. Objectives This study aimed to determine the prevalence of UTIs and urosepsis following TRUS-Bx and to assess the spectrum of pathogens and antibiotic resistance patterns among affected patients. Methods This prospective descriptive cross-sectional study was conducted in the Department of Urology, Sindh Institute of Urology and Transplantation (SIUT), Karachi, from November 3, 2021, to May 2, 2022. A total of 149 male patients aged 45-80 years with lower urinary tract symptoms, elevated prostate-specific antigen (PSA > 4 ng/mL), or palpable nodules on digital rectal examination were enrolled. Patients with uncontrolled diabetes mellitus, catheterization, bladder stones, pre-biopsy UTI, or positive urine culture were excluded. Pre-biopsy rectal swabs were obtained to guide targeted antimicrobial prophylaxis. Follow-up was performed on the seventh post-procedure day with complete blood count, urine culture, and blood culture irrespective of symptoms. Data were analyzed using IBM SPSS Statistics for Windows, Version 20.0 (Released 2011; IBM Corp., Armonk, NY, USA). Results Among 149 patients, four (2.68%) developed UTIs, while none developed urosepsis. Urine cultures revealed bacterial growth in 69 patients (46.3%), with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.